Hepatocellular carcinoma (HCC) is one of the most common cancers in the world (Okuda, 1992) . HCC is associated with well-de®ned viral and non-viral etiological factors. Chronic infection with hepatitis B or C virus, chemical carcinogens (i.e., a¯atoxins), and other environmental and host factors causing liver injury have etiologically been linked to HCC (Ozturk, 1999) . Various genetic and epigenetic abnormalities have been identi®ed in HCC, suggesting a multi-step nature of hepatocarcinogenesis (Ozturk, 1999) . Although a number of genetic and epigenetic alterations have been reported in HCC, each alteration appears to be implicated in a limited fraction of HCC (Ozturk, 1999) . Nevertheless, when combined, alterations of cell cycle-related genes, including p16, p21, p27, cyclin A, cyclin D1, cyclin E, and Rb genes, are seen in the vast majority of HCCs (Nishida et al., 1997; Ozturk, 1999) . These ®ndings suggest that disruption of the cell cycle-related genes plays a crucial role in hepatocarcinogenesis (Kamb, 1995) .
Cells respond to DNA damage by stopping the cell cycle either at a G1 or G2 DNA-damage checkpoint. In contrast to the G1 checkpoint, the mechanisms controlling the G2 checkpoint have remained unclear until recently. A model now exists for epithelial cells in which distinct members of the 14-3-3 family target speci®c mitotic regulators to control various aspects of the G2 checkpoint (Hermeking et al., 1997; el-Deiry, 1998; Piwnica-Worms, 1999) .
The 14-3-3 s gene, one of the seven members of the 14-3-3 family, has recently received much attention. The 14-3-3 s gene was originally characterized as an epithelial-speci®c marker, HME1 (Prasad et al., 1992) . This gene has been shown to be responsible for G2 cell cycle checkpoint control by p53 in response to DNA damage in human cells (Hermeking et al., 1997) . It has been suggested that 14-3-3 s normally sequesters cdc2-cyclin B1 complexes in the cytoplasm during G2 arrest, and that the absence of 14-3-3 s eventually allows cdc2-cyclin B1 complexes to enter the nucleus, resulting in mitotic catastrophe . Moreover, Laronga et al. (2000) have recently shown that 14-3-3 s can bind Cdk2, Cdc2, and Cdk4 and sequester them in the cytoplasm through nuclear exporting activities. Therefore, they have de®ned 14-3-3 s as a new class of Cdk inhibitor (Laronga et al., 2000) .
Several lines of evidence suggest a link between loss of 14-3-3 s function and cell transformation. The 14-3- The ®rst two authors contributed equally to this work.
3 s gene has been shown to suppress the anchorageindependent growth of some breast cancer cell lines (Laronga et al., 2000) . Down-regulation of 14-3-3 s expression has been reported in v-Ha-ras-transformed mammary epithelial cells, mammary carcinoma cells (Prasad et al., 1992) , SV40-transformed human keratinocytes (Dellambra et al., 1995) , head and neck squamous cell carcinoma lines (Vellucci et al., 1995) , primary bladder tumors (Ostergaard et al., 1997) , and colonic polyp specimens (Melis and White, 1999) . The implication of loss of 14-3-3 s function in tumorigenesis was further substantiated by the results of a recent study showing hypermethylation of CpG islands and transcriptional silencing of the 14-3-3 s gene in the majority of breast cancers (Ferguson et al., 2000) . These ®ndings suggest that loss of 14-3-3 s function, often due to hypermethylation of CpG islands, is a crucial event in the pathogenesis of breast cancer (Ferguson et al., 2000) . Although the precise mechanisms leading to the aberrant methylation of CpG islands in neoplastic cells are not known Jones and Laird, 1999) , frequent methylation of the p16 promoter in HCC (Chaubert et al., 1997; Liew et al., 1999; Matsuda et al., 1999; Wong et al., 1999) suggests that epigenetic inactivation of tumor suppressor genes plays an important role in HCC (Herman, 1999; Kanai et al., 2000) . Therefore, it seems signi®cant to examine the methylation status of the 14-3-3 s gene in HCC.
A DNA methylation assay technique, termed bisul®te-PCR-single strand conformation polymorphism (BiPS) or bisul®te-single strand conformation polymorphism (bisul®te-SSCP), is a combination of sodium bisul®te modi®cation and PCR-SSCP (Burri and Chaubert, 1999; Maekawa et al., 1999; Suzuki et al., 2000) . Methylated and unmethylated alleles migrate dierentially because of their dierence in conformation. After bisul®te treatment followed by PCR ampli®cation, methylated and unmethylated alleles can be simultaneously separated in a non-denaturing gel. We ®rst tested this technique to detect methylation of the 14-3-3 s gene in breast carcinoma cell lines that had already been characterized for the methylation status of this gene (Ferguson et al., 2000) . DNAs from two 14-3-3 s methylation-positive breast cancer cell lines, Hs578T and MDA-MB-435, and methylationnegative breast cancer cell lines, MCF-7 and MDA-MB-231, were subjected to sodium bisulfate modi®ca-tion as previously described (Herman et al., 1996) . Bisul®te-modi®ed DNA was ampli®ed using primers that encompass the ®rst exon of the 14-3-3 s gene, of which a sense primer was end-labeled with Cy5. (Ferguson et al., 2000) . PCR products were subjected to non-denaturing gel electrophoresis and analysed by an automated DNA sequencer (Suzuki et al., 2000) . Methylation-positive cell lines showed distinct peaks compared with the methylation-negative cell lines (Figure 1 and data not shown). The results were con®rmed by DNA sequencing, suggesting that bisul®te-SSCP could be applied to methylation analysis of the 14-3-3 s gene.
The methylation status of CpG islands of the 14-3-3 s gene was then analysed in HCC tissues by bisul®te-SSCP. Genomic DNAs extracted from four normal liver tissues and 19 paired specimens of carcinoma and adjacent non-tumorous liver tissues were subjected to bisul®te-SSCP. Non-tumorous liver tissues consisted of 16 tissues with cirrhosis and three tissues with chronic hepatitis. PCR products from the methylated and unmethylated cell lines were used as positive and negative controls, respectively. All of the four normal liver tissues, 12 of the 19 tissues with cirrhosis or hepatitis, and two of the 19 carcinoma tissues showed the same peaks as those of the negative controls (Figure 1) . In contrast, a single extra peak, which migrated at the same position as the control completely methylated DNA, was observed in 14 carcinomas (Figure 1 ). The sequencing results showed that the single extra peak consisted only of completely methylated DNA (Figure 2 and data not shown). Three HCC samples, six tissues with cirrhosis, and one tissue with hepatitis showed heterogenous peaks (Figure 1 and data not shown) . Subsequent sequencing analysis revealed that these samples had partially methylated alleles. Of the 14 CpG dinucleotides analysed, two carcinoma cases showed methylation at 12 CpG sites and the remaining one had 10 methylated CpG sites (data not shown). The levels of methylation in non-tumorous liver tissues were lower than those in carcinomas. Three cirrhotic tissues showed methylation at four CpG sites and the remaining three had three methylated CpG sites, and one hepatitis tissue showed Figure 1 Bisul®te-SSCP analysis of the 14-3-3 s gene in HCC tissues. Genomic DNAs extracted from four normal liver tissues and 19 paired specimens of carcinoma and adjacent nontumorous liver tissues were subjected to sodium bisul®te modi®cation as previously described (Herman et al., 1996) . Bisul®te-modi®ed DNA was ampli®ed using primers that encompass the ®rst exon of the 14-3-3 s gene. Primer sequences were 5'-AGAAGGTTAAGTTGGTAGAGTAGG-3' (sense) and 5'-CCTAAAACTCAATCTCCACCTTCTC (antisense). Only sense primer was end-labeled with Cy5 such that only sense DNAs were recognized by an automated DNA sequencer. One ml of each PCR product was mixed with 10 ml of loading buer (95% formamide, 20 mM EDTA, 0.05% xylen cyanol, and 0.05% bromophenol blue). The samples were heated at 958C for 5 min, followed by rapid chilling on ice for 5 min, and subjected to electrophoresis on a 5% non-denaturing polyacrylamide gel containing 5% glycerol at 308C in an ALF express automated DNA sequencer (Pharmacia Biotech, Uppsala, Sweden). Data were then analysed using the Fragment Manager Software (Pharmacia Biotech). M, methylation peaks: U, unmethylation peaks Oncogene Methylation and loss of expression of 14-3-3 s in HCC N Iwata et al methylation at three CpG sites (data not shown). Taken together, 89% (17/19) of the HCC tissues exhibited complete or partial methylation of the 14 CpG dinucleotides. There was no signi®cant statistical correlation between methylation of the 14-3-3 s gene and clinicopathological characteristics such as age, types of viral infection, tumor size, and tumor cell dierentiation (data not shown). These results suggest that hypermethylation of the 14-3-3 s gene is one of the early events in the development of HCC. All of the HCC samples analysed in the present study were associated with chronic hepatitis B or C virus infections. Therefore, further analysis, including analysis of non-virus-associated HCCs and cirrhosis, is needed to clarify whether hypermethylation of the 14-3-3 s gene is related to speci®c etiological factors such as chronic infections with hepatitis viruses.
To determine the signi®cance of hypermethylation of the 14-3-3 s gene, we immunohistochemically analysed 14-3-3 s expression in 14 methylation-positive HCCs, two methylation-negative HCCs, and four normal liver tissues using a monoclonal antibody speci®c for 14-3-3 s. Of the 19 HCC samples analysed by bisul®te-SSCP, three cases were not analysed for 14-3-3 s expression because paran blocks were not available. All of the four normal liver tissues and both of the methylation-negative HCC samples showed positive cytoplasmic staining for 14-3-3 s. (Figure 3a and data not shown). These immunoreactivities were totally blocked by a speci®c 14-3-3 s blocking peptide, attesting to the speci®city of the antibody (data not shown). In contrast, all of the 14 HCC samples with hypermethylation showed loss of expression ( Figure  3b) , and a signi®cant correlation between methylation and loss of expression was observed (P50.01, Fisher's exact test). Cytoplasmic staining of 14-3-3 s was observed in all of the 16 adjacent non-tumorous liver tissues irrespective of the methylation status (Figure 3b and data not shown). Treatment of a methylationpositive HCC cell line. HLE, with 5-aza-2'-deoxycytidine (5-aza-dC) resulted in demethylation of the gene and synthesis of 14-3-3 s mRNA and protein ( Figure  4 ), indicating that hypermethylation plays a causal role in inactivation of the 14-3-3 s gene in HCC.
Unmethylated peaks were observed in almost all of the methylation-positive cases (Figure 1) . One possible explanation is that these unmethylated peaks were due to contaminated normal tissues in the tumor, such as in¯ammatory cells and normal liver cells. Considering the loss of expression, it is reasonable to speculate that both alleles are inactivated by biallelic methylation or methylation in conjunction with genetic alterations, such as mutation and loss of heterozygosity (LOH) (Ferguson et al., 2000) . The 14-3-3 s gene has been localized to chromosome 1p35 (Hermeking et al., 1997) . Although frequent LOH on 1p has been reported in HCC (Nagai et al., 1997) , it is not known whether the region lost in HCC includes the 14-3-3 s gene. LOH at the 14-3-3 s locus was examined using primers that amplify TG repeats within the 3' untranslated region of the 14-3-3 s gene (Ferguson et al., 2000) . LOH was not observed in any of the 10 informative cases (data not shown). Mutations in the 14-3-3 s gene were then examined by SSCP, but no mutations were detected in any of the 19 HCC samples (data not shown). These results suggest that epigenetic Figure 2 DNA sequencing results. Sequence reactions were performed using the Auto Read Sequencing Kit (Pharmacia Biotech) and samples were loaded on a 6% urea-polyacrylamide denaturing gels in the ALF express automated DNA sequencer. CpG sites are underlined. (A) Original sequence of the 14-3-3 s gene. (B) Sequence of the 14-3-3 s gene following sodium bisul®te treatment of normal liver DNA. All cytosine residues were converted to thymine. (c) Sequence of the 14-3-3 s gene following sodium bisul®te treatment of tumor DNA (case 1). All cytosine residues at CpG sites remained as cytosine while other cytosines were converted to thymine (*) Figure 3 Immunohistochemistry for 14-3-3 s in HCC tissues using the anti-14-3-3 s antibody. Goat anti-14-3-3 s polyclonal antibody (N-14) and its blocking peptide were purchased from Santa Cruz Biotechnology (Santa Cruz. CA, USA). Immunohistochemistry was performed as previously described (Yamamoto et al., 1999) . Several sections were also incubated with the 14-3-3 sblocking peptide to demonstrate the speci®city of the antibody. (a) Cytoplasmic immunostaining for 14-3-3 s in a HCC specimen negative for 14-3-3 s methylation. 4006magni®cation. (b) Loss of 14-3-3 s expression in a HCC specimen positive for 14-3-3 s methylation. 4006magni®cation. Note that cirrhotic cells adjacent to carcinoma cells showed positive cytoplasmic staining inactivation is the main mechanism underlying the loss of 14-3-3 s expression in HCC.
Cirrhosis and chronic hepatitis associated with hepatitis virus infections have been thought to be preneoplastic lesions. In this regard, it is notable that methylation of the 14-3-3 s gene was detected not only in carcinoma tissues but also in adjacent tissues with cirrhosis or chronic hepatitis. De novo methylation of genes appears to be an early and frequent event in most neoplasias (Ahuja et al., 1998) . Aberrant methylation of the p16 promoter has been reported in early preneoplastic lesions in the lung (Belinsky et al., 1998) , colon (Hsieh et al., 1998) , esophagus , pancreas (Wilentz et al., 1998) , and liver . However, since lower levels of methylation found in tissues with cirrhosis or hepatitis did not aect the 14-3-3 s expression in the present study, the signi®cance of methylation is not clear. These lower levels of methylation may be age-related alterations (Ahuja et al., 1998) . Several studies have shown that gene activity is inversely correlated with the density of gene-speci®c CpG island methylation (Hsieh, 1994) . Accumulation of methylated cytosine in the 5' CpG island of the p16 gene reportedly silences this gene in a dose-dependent and progressive manner (Matsuda et al., 1999; Gonzalgo et al., 1998; Herman, 1999) . Moreover, weakly methylated alleles have been seen in cirrhotic tissues in which strongly methylated alleles were detected in the corresponding tumor tissues . Therefore, it is possible that methylation of the 14-3-3 s gene and downregulation of its expression occur in a progressive manner during hepatocarcinogenesis. Lower levels of methylation found in tissues with cirrhosis or chronic hepatitis may be due to the heterogeneity of methylation in hepatocytes. It seems intriguing to speculate that hepatocytes with loss of 14-3-3 s expression due to strong methylation are more likely to clonally expand than are those with normal function. Further analysis is needed to address these issues.
Our results con®rm recently reported observations of frequent hypermethylation of CpG islands of the 14-3-3 s gene in human cancer and extend the observations to HCC and possibly to preneoplastic lesions of the liver. Loss of the negative regulator role of the 14-3-3 s gene in cell cycle progression appears to contribute to malignant transformation by impairing the G2 cell cycle checkpoint function, thus allowing an accumulation of genetic defects. Epigenetic inactivation of the 14-3-3 s gene corresponds to one of the most common abnormalities reported in HCC to date. Detection of hypermethylation of the 14-3-3 s gene could serve as a useful screening test for the early detection of HCC in clinical samples such as blood, especially those from high risk patients (Wong et al., 1999) .
